Sarepta Therapeutics stock
SRPTNASDAQSarepta Therapeutics, Inc., HealthcareISIN US8036071004
39Score 39 out of 100, Weak
Price and trend
47 / 100
Price history
−11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 14% below it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 33% below its 52-week high. Largest decline in 20 years: 93% (December 2020 to July 2025).
Chart figures for advanced users
- SMA 50$18.73
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$18.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.86
- The lowest closing price of the last twelve months.
- Resistance$23.83
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sarepta Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.72B, is number 138 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.2B (up 15.6% year on year) and a loss of $713.41M.
- For fiscal 2026, analysts expect on average revenue of $1.84B (down 16.5%) and adjusted earnings per share of $3.08.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 554 of 702 in Healthcare, median 53.
- The P/E is 114.9 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 22.5 (Biotechnology median 21.7). The P/E therefore does not count in the score.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 32.4% a year since 2020, Biotechnology median 19.4%.Growth 59
Weaknesses
- DilutionShare count up 34% since 2020.Capital allocation 18
- Negative free cash flowFree cash flow −$31.6M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 70% a year over the last 12 months.Stability 47
Its standout strength is valuation, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 18.9% on the twelve months before. Revenue has grown strongly since 2006, at around 68% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 60%, operating −30%, net −32%. Last 12 months: net 1%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 5 Nov 2026EPS reported $0.13 (expected $0.08)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 29.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $3.08−1.9%
- Revenue
- $1.84B−0.1%
- Earnings per share
- $0.34−29.6%
- Revenue
- $1.41B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: +2.4%Net product revenue guidance narrowed to $1.2 to $1.3 billion (before: $1.2 to $1.4 billion) with a slightly weaker second half, but collaboration revenue guidance raised by $75 million.
“As Mike mentioned, consistent with our previous directional model towards the lower end of the $1.2 to $1.4 billion range, we are narrowing our 2026 total net product revenue guidance to $1.2 billion to $1.3 billion The timing of revenue reflects how patients progress from enrollment form through the treatment journey.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Sarepta Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Zenas BioPharmaZBIO $1.87B37
- ZymeworksZYME $1.84B59
- Hemab Therapeutics HoldingsCOAG $1.84B45
- uniQureQURE $1.73B35
- Kailera TherapeuticsKLRA $1.72B41
- Stoke TherapeuticsSTOK $1.71B37
- Taysha Gene TherapiesTSHA $1.71B35
- Nurix TherapeuticsNRIX $1.7B68
ETFs that hold Sarepta Therapeutics
Held by 18 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.09% | 0.49% | €26.29M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 1.28% | 0.50% | €127.64M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.18% | 0.40% | €1.5B |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.17% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.12% | 0.35% | €1.25B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.10% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.